| Name | Number of Publications | Most Recent Publication | Publications by All Authors | Concept Score | Why? | 
|---|
| Flavonoids | 25 | 2020 | 87 | 6.770 | Why? | 
| Glucuronides | 25 | 2020 | 29 | 6.690 | Why? | 
| Glucuronosyltransferase | 20 | 2021 | 72 | 5.400 | Why? | 
| Tandem Mass Spectrometry | 22 | 2020 | 292 | 4.060 | Why? | 
| Genistein | 17 | 2012 | 40 | 3.490 | Why? | 
| Intestinal Mucosa | 23 | 2019 | 815 | 2.980 | Why? | 
| Intestinal Absorption | 22 | 2015 | 193 | 2.900 | Why? | 
| Chromatography, Liquid | 14 | 2017 | 243 | 2.900 | Why? | 
| Caco-2 Cells | 30 | 2020 | 97 | 2.640 | Why? | 
| Isoflavones | 13 | 2009 | 45 | 2.460 | Why? | 
| Phenols | 7 | 2012 | 57 | 2.280 | Why? | 
| Chromatography, High Pressure Liquid | 19 | 2020 | 364 | 2.110 | Why? | 
| Microsomes, Liver | 15 | 2020 | 100 | 2.030 | Why? | 
| ATP-Binding Cassette Transporters | 8 | 2015 | 197 | 2.010 | Why? | 
| Microsomes | 10 | 2010 | 55 | 1.780 | Why? | 
| Sulfotransferases | 5 | 2017 | 28 | 1.730 | Why? | 
| Biological Availability | 23 | 2021 | 153 | 1.590 | Why? | 
| Rats | 39 | 2021 | 3882 | 1.510 | Why? | 
| Liver | 13 | 2021 | 1878 | 1.470 | Why? | 
| Plant Extracts | 5 | 2015 | 138 | 1.350 | Why? | 
| Multidrug Resistance-Associated Proteins | 7 | 2016 | 27 | 1.340 | Why? | 
| Intestines | 14 | 2021 | 615 | 1.270 | Why? | 
| Neoplasm Proteins | 5 | 2015 | 716 | 1.240 | Why? | 
| Biological Transport | 25 | 2012 | 369 | 1.210 | Why? | 
| Colon | 4 | 2019 | 379 | 1.180 | Why? | 
| Flavones | 5 | 2012 | 10 | 1.180 | Why? | 
| Dinoprostone | 2 | 2019 | 82 | 1.160 | Why? | 
| Celecoxib | 2 | 2019 | 35 | 1.140 | Why? | 
| Flavonols | 4 | 2011 | 13 | 1.140 | Why? | 
| Cyclooxygenase 2 Inhibitors | 2 | 2019 | 54 | 1.110 | Why? | 
| Animals | 65 | 2022 | 36421 | 1.030 | Why? | 
| Kinetics | 18 | 2017 | 1356 | 1.010 | Why? | 
| Raloxifene Hydrochloride | 4 | 2021 | 18 | 0.990 | Why? | 
| Models, Molecular | 4 | 2012 | 1144 | 0.930 | Why? | 
| Rats, Sprague-Dawley | 20 | 2015 | 1310 | 0.910 | Why? | 
| Flavanones | 4 | 2012 | 8 | 0.860 | Why? | 
| Apigenin | 8 | 2012 | 9 | 0.850 | Why? | 
| Isoenzymes | 4 | 2011 | 231 | 0.830 | Why? | 
| Glucuronidase | 3 | 2022 | 32 | 0.820 | Why? | 
| Molecular Structure | 10 | 2015 | 320 | 0.820 | Why? | 
| Administration, Oral | 11 | 2017 | 727 | 0.780 | Why? | 
| Cytochrome P-450 Enzyme System | 5 | 2015 | 142 | 0.780 | Why? | 
| Ginsenosides | 2 | 2012 | 20 | 0.750 | Why? | 
| Recombinant Proteins | 9 | 2016 | 1439 | 0.720 | Why? | 
| Protein Isoforms | 7 | 2011 | 429 | 0.700 | Why? | 
| Metabolic Detoxication, Phase II | 3 | 2015 | 15 | 0.690 | Why? | 
| Hydroxyl Radical | 1 | 2020 | 14 | 0.670 | Why? | 
| Anticarcinogenic Agents | 3 | 2012 | 54 | 0.660 | Why? | 
| Serum Albumin, Bovine | 1 | 2020 | 56 | 0.660 | Why? | 
| Spectrophotometry, Ultraviolet | 2 | 2010 | 50 | 0.650 | Why? | 
| Rats, Wistar | 8 | 2020 | 398 | 0.640 | Why? | 
| Perfusion | 10 | 2020 | 214 | 0.620 | Why? | 
| Intestine, Small | 3 | 2008 | 317 | 0.620 | Why? | 
| Diterpenes | 2 | 2015 | 29 | 0.570 | Why? | 
| Camptothecin | 2 | 2016 | 78 | 0.560 | Why? | 
| Models, Biological | 9 | 2012 | 1535 | 0.560 | Why? | 
| Pharmaceutical Preparations | 3 | 2012 | 91 | 0.550 | Why? | 
| Mixed Function Oxygenases | 4 | 2003 | 36 | 0.540 | Why? | 
| Polymyxin B | 3 | 2012 | 47 | 0.530 | Why? | 
| Dipeptidases | 5 | 2003 | 15 | 0.520 | Why? | 
| Cholesterol 7-alpha-Hydroxylase | 1 | 2016 | 35 | 0.510 | Why? | 
| Protein-Tyrosine Kinases | 1 | 2017 | 231 | 0.510 | Why? | 
| Lactones | 2 | 2015 | 40 | 0.510 | Why? | 
| Mangifera | 1 | 2015 | 2 | 0.500 | Why? | 
| Gallic Acid | 1 | 2015 | 4 | 0.500 | Why? | 
| Hydrolyzable Tannins | 1 | 2015 | 4 | 0.500 | Why? | 
| Colorectal Neoplasms | 2 | 2019 | 650 | 0.500 | Why? | 
| Seeds | 1 | 2015 | 43 | 0.480 | Why? | 
| Reproducibility of Results | 8 | 2017 | 3032 | 0.480 | Why? | 
| Stilbenes | 1 | 2015 | 42 | 0.480 | Why? | 
| Curcumin | 1 | 2015 | 42 | 0.480 | Why? | 
| Substrate Specificity | 7 | 2012 | 313 | 0.480 | Why? | 
| Humans | 70 | 2020 | 133705 | 0.480 | Why? | 
| Estrone | 2 | 2004 | 13 | 0.450 | Why? | 
| Drugs, Chinese Herbal | 2 | 2011 | 24 | 0.450 | Why? | 
| Gastrointestinal Microbiome | 1 | 2022 | 824 | 0.440 | Why? | 
| Cholestasis | 1 | 2016 | 158 | 0.440 | Why? | 
| Male | 40 | 2020 | 65850 | 0.440 | Why? | 
| Antineoplastic Agents | 5 | 2011 | 1850 | 0.430 | Why? | 
| Dietary Supplements | 2 | 2010 | 486 | 0.430 | Why? | 
| Biomarkers | 5 | 2019 | 3430 | 0.420 | Why? | 
| Sensitivity and Specificity | 6 | 2017 | 2165 | 0.410 | Why? | 
| Protein Kinase Inhibitors | 1 | 2017 | 609 | 0.400 | Why? | 
| Panax | 1 | 2012 | 7 | 0.390 | Why? | 
| Estrous Cycle | 1 | 2012 | 36 | 0.390 | Why? | 
| Lactase-Phlorizin Hydrolase | 2 | 2012 | 21 | 0.380 | Why? | 
| Pterocarpans | 2 | 2011 | 2 | 0.380 | Why? | 
| Sulfur Compounds | 1 | 2011 | 4 | 0.380 | Why? | 
| Dogs | 6 | 2016 | 798 | 0.380 | Why? | 
| Drug Evaluation, Preclinical | 2 | 2011 | 159 | 0.370 | Why? | 
| Alkaloids | 3 | 2011 | 37 | 0.370 | Why? | 
| Cephalosporins | 4 | 1996 | 143 | 0.370 | Why? | 
| Quinolizines | 2 | 2011 | 7 | 0.350 | Why? | 
| Trifolium | 2 | 2008 | 2 | 0.350 | Why? | 
| Hot Temperature | 2 | 2008 | 146 | 0.350 | Why? | 
| Hypericum | 1 | 2010 | 1 | 0.340 | Why? | 
| Quinazolines | 2 | 2004 | 184 | 0.340 | Why? | 
| Coumarins | 2 | 2015 | 24 | 0.340 | Why? | 
| Monosaccharide Transport Proteins | 1 | 2010 | 43 | 0.330 | Why? | 
| Drug Interactions | 6 | 2010 | 261 | 0.320 | Why? | 
| Tissue Distribution | 6 | 2012 | 400 | 0.320 | Why? | 
| Estrogens | 1 | 2012 | 523 | 0.320 | Why? | 
| Sulfates | 3 | 2016 | 37 | 0.320 | Why? | 
| Mice | 16 | 2017 | 18948 | 0.320 | Why? | 
| Gastrointestinal Tract | 3 | 2022 | 243 | 0.320 | Why? | 
| RNA, Small Interfering | 2 | 2011 | 714 | 0.320 | Why? | 
| Phytoestrogens | 2 | 2007 | 16 | 0.310 | Why? | 
| Biotransformation | 5 | 2012 | 56 | 0.310 | Why? | 
| Hydrolysis | 6 | 2012 | 164 | 0.310 | Why? | 
| Injections, Intravenous | 5 | 2012 | 252 | 0.300 | Why? | 
| Epimedium | 1 | 2008 | 1 | 0.300 | Why? | 
| Anti-Bacterial Agents | 6 | 2012 | 2569 | 0.290 | Why? | 
| Nucleosides | 3 | 2004 | 19 | 0.290 | Why? | 
| Quantitative Structure-Activity Relationship | 3 | 2012 | 15 | 0.280 | Why? | 
| Organic Anion Transporters | 3 | 2020 | 21 | 0.280 | Why? | 
| HeLa Cells | 3 | 2015 | 831 | 0.270 | Why? | 
| Morphinans | 1 | 2006 | 2 | 0.270 | Why? | 
| Bridged-Ring Compounds | 1 | 2006 | 17 | 0.270 | Why? | 
| Benzoates | 1 | 2006 | 23 | 0.260 | Why? | 
| Mice, Knockout | 6 | 2015 | 3991 | 0.260 | Why? | 
| Glucosides | 1 | 2006 | 48 | 0.260 | Why? | 
| Madin Darby Canine Kidney Cells | 2 | 2016 | 11 | 0.250 | Why? | 
| Bile | 3 | 2012 | 47 | 0.250 | Why? | 
| Cephalexin | 2 | 1996 | 7 | 0.250 | Why? | 
| Hydrogen-Ion Concentration | 8 | 2004 | 469 | 0.250 | Why? | 
| Up-Regulation | 1 | 2009 | 905 | 0.250 | Why? | 
| Inactivation, Metabolic | 2 | 2016 | 34 | 0.250 | Why? | 
| gamma-Glutamyl Hydrolase | 1 | 2005 | 10 | 0.240 | Why? | 
| Permeability | 3 | 2012 | 131 | 0.240 | Why? | 
| Dipeptides | 4 | 1995 | 62 | 0.240 | Why? | 
| Biological Products | 1 | 2007 | 137 | 0.230 | Why? | 
| Food Labeling | 1 | 2004 | 11 | 0.230 | Why? | 
| Soybean Proteins | 1 | 2004 | 17 | 0.230 | Why? | 
| Rats, Inbred F344 | 3 | 2021 | 109 | 0.230 | Why? | 
| Polyphenols | 3 | 2010 | 25 | 0.220 | Why? | 
| Binding Sites | 3 | 2012 | 1377 | 0.220 | Why? | 
| Area Under Curve | 4 | 2012 | 333 | 0.220 | Why? | 
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 315 | 0.220 | Why? | 
| Enzyme Inhibitors | 3 | 2009 | 608 | 0.220 | Why? | 
| Methionine | 2 | 1994 | 105 | 0.220 | Why? | 
| Species Specificity | 4 | 2011 | 569 | 0.220 | Why? | 
| Linear Models | 2 | 2016 | 723 | 0.220 | Why? | 
| Absorption | 3 | 2012 | 53 | 0.220 | Why? | 
| Ginkgo biloba | 1 | 2003 | 12 | 0.210 | Why? | 
| Cytochrome P-450 CYP1A2 | 1 | 2003 | 49 | 0.200 | Why? | 
| Precision Medicine | 2 | 2017 | 355 | 0.200 | Why? | 
| Carrier Proteins | 3 | 2005 | 1067 | 0.200 | Why? | 
| Injections, Intraperitoneal | 2 | 2012 | 74 | 0.200 | Why? | 
| Metabolic Networks and Pathways | 3 | 2007 | 197 | 0.190 | Why? | 
| Propionates | 3 | 2009 | 33 | 0.190 | Why? | 
| Metabolic Clearance Rate | 3 | 2012 | 145 | 0.190 | Why? | 
| Feces | 2 | 2016 | 788 | 0.190 | Why? | 
| DNA, Complementary | 3 | 2003 | 471 | 0.180 | Why? | 
| Catalytic Domain | 2 | 2012 | 177 | 0.180 | Why? | 
| Cytochrome P-450 CYP3A | 4 | 2012 | 60 | 0.180 | Why? | 
| Quinolines | 3 | 2009 | 113 | 0.180 | Why? | 
| Hepatobiliary Elimination | 1 | 2020 | 1 | 0.170 | Why? | 
| Emodin | 2 | 2010 | 2 | 0.170 | Why? | 
| Cell Membrane Permeability | 4 | 2004 | 77 | 0.170 | Why? | 
| Enterohepatic Circulation | 1 | 2020 | 11 | 0.170 | Why? | 
| Membrane Transport Proteins | 3 | 2015 | 186 | 0.170 | Why? | 
| Cell Line | 6 | 2015 | 2841 | 0.170 | Why? | 
| Portal Vein | 1 | 2020 | 95 | 0.170 | Why? | 
| Amino Acid Sequence | 5 | 2012 | 2789 | 0.160 | Why? | 
| Temperature | 5 | 2004 | 329 | 0.160 | Why? | 
| Protein Conformation | 2 | 2012 | 871 | 0.160 | Why? | 
| Mammary Tumor Virus, Mouse | 1 | 1999 | 107 | 0.160 | Why? | 
| Oxidoreductases | 1 | 1999 | 103 | 0.150 | Why? | 
| Peptides | 4 | 1996 | 860 | 0.150 | Why? | 
| Gene Silencing | 2 | 2011 | 247 | 0.150 | Why? | 
| Leukotriene C4 | 2 | 2011 | 4 | 0.150 | Why? | 
| Hepatocytes | 1 | 2020 | 241 | 0.150 | Why? | 
| In Vitro Techniques | 4 | 2009 | 992 | 0.150 | Why? | 
| Cattle | 1 | 2020 | 587 | 0.150 | Why? | 
| Reference Standards | 2 | 2010 | 246 | 0.150 | Why? | 
| Prodrugs | 3 | 2003 | 63 | 0.150 | Why? | 
| Thymidylate Synthase | 1 | 1998 | 23 | 0.150 | Why? | 
| Genetic Vectors | 2 | 1999 | 970 | 0.150 | Why? | 
| Limit of Detection | 2 | 2015 | 77 | 0.140 | Why? | 
| HEK293 Cells | 1 | 2020 | 814 | 0.140 | Why? | 
| Cyclosporine | 2 | 2011 | 148 | 0.140 | Why? | 
| Midazolam | 2 | 2012 | 47 | 0.140 | Why? | 
| Tumor Cells, Cultured | 4 | 2011 | 1102 | 0.140 | Why? | 
| Carcinoma, Hepatocellular | 2 | 2017 | 1000 | 0.140 | Why? | 
| Isotope Labeling | 1 | 2017 | 106 | 0.140 | Why? | 
| Lipase | 1 | 1997 | 98 | 0.140 | Why? | 
| Gene Expression | 2 | 2017 | 1616 | 0.130 | Why? | 
| Kidney | 2 | 2016 | 1418 | 0.130 | Why? | 
| Polymorphism, Genetic | 1 | 2000 | 897 | 0.130 | Why? | 
| Healthy Volunteers | 1 | 2017 | 153 | 0.130 | Why? | 
| Biological Assay | 1 | 2017 | 111 | 0.130 | Why? | 
| Aryl Hydrocarbon Hydroxylases | 1 | 1996 | 44 | 0.130 | Why? | 
| Swine, Miniature | 1 | 2016 | 53 | 0.130 | Why? | 
| Phenylalanine | 3 | 2000 | 134 | 0.130 | Why? | 
| Enzyme Activation | 1 | 2017 | 645 | 0.120 | Why? | 
| Tetrahydroisoquinolines | 1 | 1995 | 5 | 0.120 | Why? | 
| Liver Neoplasms | 2 | 2017 | 1410 | 0.120 | Why? | 
| Cell Line, Transformed | 1 | 2015 | 169 | 0.120 | Why? | 
| Isoquinolines | 1 | 1995 | 42 | 0.120 | Why? | 
| Epithelium | 5 | 1994 | 366 | 0.120 | Why? | 
| Carcinogens | 3 | 2011 | 160 | 0.120 | Why? | 
| Stereoisomerism | 2 | 2011 | 119 | 0.120 | Why? | 
| Isomerism | 2 | 2011 | 30 | 0.120 | Why? | 
| Biocatalysis | 2 | 2012 | 37 | 0.120 | Why? | 
| Osmolar Concentration | 2 | 2011 | 179 | 0.110 | Why? | 
| Jejunum | 3 | 2012 | 131 | 0.110 | Why? | 
| Cells, Cultured | 5 | 2011 | 3173 | 0.110 | Why? | 
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1995 | 226 | 0.110 | Why? | 
| Zidovudine | 1 | 1993 | 23 | 0.110 | Why? | 
| Enzyme Stability | 2 | 2007 | 60 | 0.110 | Why? | 
| Thymidine | 1 | 1993 | 55 | 0.110 | Why? | 
| Verapamil | 2 | 2011 | 58 | 0.100 | Why? | 
| Cell Line, Tumor | 3 | 2012 | 3754 | 0.100 | Why? | 
| Amino Acids | 3 | 1994 | 687 | 0.100 | Why? | 
| Teichoic Acids | 1 | 2012 | 13 | 0.100 | Why? | 
| Diketopiperazines | 1 | 2012 | 4 | 0.100 | Why? | 
| Kidney Tubular Necrosis, Acute | 1 | 2012 | 9 | 0.100 | Why? | 
| Swine | 1 | 2016 | 1215 | 0.100 | Why? | 
| Phloretin | 1 | 2012 | 3 | 0.100 | Why? | 
| Anesthetics, Intravenous | 1 | 2012 | 47 | 0.100 | Why? | 
| Arylsulfotransferase | 1 | 2012 | 6 | 0.100 | Why? | 
| Kaempferols | 1 | 2012 | 6 | 0.100 | Why? | 
| Heterocyclic Compounds, 4 or More Rings | 1 | 2012 | 34 | 0.100 | Why? | 
| Structural Homology, Protein | 1 | 2012 | 27 | 0.100 | Why? | 
| Aconitine | 1 | 2011 | 9 | 0.100 | Why? | 
| Sex Characteristics | 2 | 2011 | 335 | 0.100 | Why? | 
| Uridine Diphosphate Glucuronic Acid | 1 | 2011 | 6 | 0.090 | Why? | 
| Membrane Transport Modulators | 1 | 2011 | 5 | 0.090 | Why? | 
| Hydrogen Bonding | 1 | 2012 | 87 | 0.090 | Why? | 
| Ovariectomy | 1 | 2012 | 188 | 0.090 | Why? | 
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 65 | 0.090 | Why? | 
| Inflammation | 2 | 2017 | 1591 | 0.090 | Why? | 
| Time Factors | 5 | 2012 | 6585 | 0.090 | Why? | 
| Molecular Sequence Data | 4 | 2012 | 3971 | 0.090 | Why? | 
| Microbial Sensitivity Tests | 2 | 2012 | 833 | 0.090 | Why? | 
| Kidney Tubules, Proximal | 1 | 2012 | 112 | 0.090 | Why? | 
| Protein Structure, Secondary | 1 | 2012 | 256 | 0.090 | Why? | 
| Adenosine | 1 | 2012 | 140 | 0.090 | Why? | 
| Solubility | 1 | 2011 | 145 | 0.090 | Why? | 
| Glycosides | 1 | 2011 | 7 | 0.090 | Why? | 
| Molecular Sequence Annotation | 1 | 2012 | 162 | 0.090 | Why? | 
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 110 | 0.090 | Why? | 
| Cytosol | 1 | 2011 | 168 | 0.090 | Why? | 
| Catalysis | 1 | 2011 | 138 | 0.090 | Why? | 
| Calibration | 1 | 2011 | 100 | 0.090 | Why? | 
| Crystallography, X-Ray | 1 | 2012 | 394 | 0.090 | Why? | 
| Acinetobacter baumannii | 1 | 2011 | 46 | 0.090 | Why? | 
| Cell Division | 3 | 1999 | 773 | 0.090 | Why? | 
| Lipopolysaccharides | 1 | 2012 | 320 | 0.090 | Why? | 
| Klebsiella pneumoniae | 1 | 2011 | 88 | 0.090 | Why? | 
| Drug Stability | 4 | 1999 | 62 | 0.090 | Why? | 
| Testosterone | 3 | 2009 | 618 | 0.080 | Why? | 
| Mouth Neoplasms | 1 | 2011 | 115 | 0.080 | Why? | 
| Levodopa | 1 | 1990 | 92 | 0.080 | Why? | 
| Female | 12 | 2021 | 71603 | 0.080 | Why? | 
| Sequence Alignment | 1 | 2012 | 631 | 0.080 | Why? | 
| Gas Chromatography-Mass Spectrometry | 1 | 2010 | 85 | 0.080 | Why? | 
| Quality Control | 1 | 2010 | 126 | 0.080 | Why? | 
| Cathartics | 1 | 2010 | 31 | 0.080 | Why? | 
| Methotrexate | 1 | 2012 | 354 | 0.080 | Why? | 
| Protein Structure, Tertiary | 1 | 2012 | 786 | 0.080 | Why? | 
| Dipyridamole | 1 | 2009 | 22 | 0.080 | Why? | 
| Leukotriene Antagonists | 1 | 2009 | 17 | 0.080 | Why? | 
| Random Allocation | 1 | 2010 | 448 | 0.080 | Why? | 
| Sodium | 3 | 1998 | 309 | 0.080 | Why? | 
| Pseudomonas aeruginosa | 1 | 2011 | 179 | 0.080 | Why? | 
| Mice, Inbred Strains | 1 | 2010 | 321 | 0.080 | Why? | 
| Phosphodiesterase Inhibitors | 1 | 2009 | 52 | 0.080 | Why? | 
| Butanols | 1 | 2009 | 3 | 0.080 | Why? | 
| Mannitol | 3 | 2000 | 49 | 0.080 | Why? | 
| Rats, Gunn | 1 | 2009 | 3 | 0.080 | Why? | 
| Glucuronic Acid | 1 | 2009 | 14 | 0.080 | Why? | 
| Berberine | 1 | 2009 | 9 | 0.080 | Why? | 
| Methyldopa | 1 | 1989 | 4 | 0.080 | Why? | 
| Captopril | 1 | 1988 | 27 | 0.080 | Why? | 
| Indomethacin | 1 | 2009 | 86 | 0.080 | Why? | 
| Azetidines | 1 | 2009 | 63 | 0.080 | Why? | 
| Drug Resistance, Bacterial | 1 | 2012 | 383 | 0.080 | Why? | 
| Epithelial Cells | 3 | 2004 | 936 | 0.080 | Why? | 
| Hydroxylation | 2 | 2011 | 51 | 0.080 | Why? | 
| Hesperidin | 1 | 2008 | 2 | 0.080 | Why? | 
| Glucosidases | 1 | 2008 | 3 | 0.070 | Why? | 
| Prenylation | 1 | 2008 | 2 | 0.070 | Why? | 
| Ezetimibe | 1 | 2009 | 98 | 0.070 | Why? | 
| Antihypertensive Agents | 1 | 1990 | 410 | 0.070 | Why? | 
| Fungal Proteins | 1 | 2008 | 143 | 0.070 | Why? | 
| Models, Theoretical | 1 | 2009 | 398 | 0.070 | Why? | 
| Monoterpenes | 1 | 2006 | 5 | 0.070 | Why? | 
| Dose-Response Relationship, Drug | 2 | 2005 | 1735 | 0.070 | Why? | 
| Organ Specificity | 1 | 2007 | 444 | 0.070 | Why? | 
| Rats, Inbred Strains | 1 | 2006 | 236 | 0.060 | Why? | 
| Digoxin | 1 | 2006 | 44 | 0.060 | Why? | 
| NF-kappa B | 1 | 2009 | 482 | 0.060 | Why? | 
| Anticholesteremic Agents | 1 | 2009 | 245 | 0.060 | Why? | 
| Escherichia coli | 1 | 2012 | 1027 | 0.060 | Why? | 
| Sex Factors | 1 | 2010 | 1384 | 0.060 | Why? | 
| Transfection | 2 | 1999 | 1090 | 0.060 | Why? | 
| Half-Life | 1 | 2005 | 160 | 0.060 | Why? | 
| Carcinoma, Squamous Cell | 1 | 2011 | 872 | 0.060 | Why? | 
| Plants | 1 | 2005 | 52 | 0.060 | Why? | 
| Clinical Trials as Topic | 1 | 2010 | 1154 | 0.060 | Why? | 
| Protons | 2 | 1996 | 98 | 0.060 | Why? | 
| Washington | 1 | 2004 | 35 | 0.060 | Why? | 
| Structure-Activity Relationship | 1 | 2006 | 612 | 0.060 | Why? | 
| Acute Kidney Injury | 1 | 2012 | 697 | 0.060 | Why? | 
| Membrane Proteins | 1 | 2012 | 1604 | 0.060 | Why? | 
| Biliary Tract | 1 | 2004 | 15 | 0.060 | Why? | 
| Serum | 1 | 2004 | 46 | 0.050 | Why? | 
| Oxidoreductases, O-Demethylating | 1 | 2003 | 1 | 0.050 | Why? | 
| Phenacetin | 1 | 2003 | 3 | 0.050 | Why? | 
| Acetophenones | 1 | 2003 | 13 | 0.050 | Why? | 
| Treatment Outcome | 1 | 2019 | 13001 | 0.050 | Why? | 
| Estrogen Antagonists | 1 | 2004 | 107 | 0.050 | Why? | 
| Binding, Competitive | 2 | 1994 | 194 | 0.050 | Why? | 
| Phytotherapy | 1 | 2003 | 51 | 0.050 | Why? | 
| Chromatography, Ion Exchange | 1 | 2003 | 67 | 0.050 | Why? | 
| Chromatography, Gel | 1 | 2003 | 97 | 0.050 | Why? | 
| Models, Animal | 1 | 2005 | 483 | 0.050 | Why? | 
| Blotting, Northern | 1 | 2003 | 270 | 0.050 | Why? | 
| Methylation | 1 | 2003 | 231 | 0.050 | Why? | 
| Culture Media | 2 | 2012 | 184 | 0.050 | Why? | 
| Drug Resistance | 1 | 2003 | 264 | 0.050 | Why? | 
| Propranolol | 2 | 2000 | 130 | 0.050 | Why? | 
| beta-Glucosidase | 1 | 2002 | 2 | 0.050 | Why? | 
| Ciprofloxacin | 1 | 2002 | 68 | 0.050 | Why? | 
| Colonic Neoplasms | 1 | 2005 | 271 | 0.050 | Why? | 
| Apoptosis | 1 | 2009 | 1928 | 0.050 | Why? | 
| 2,4-Dinitrophenol | 2 | 1992 | 3 | 0.050 | Why? | 
| Dinitrophenols | 2 | 1992 | 5 | 0.050 | Why? | 
| Glucuronates | 1 | 2021 | 8 | 0.050 | Why? | 
| Cloning, Molecular | 1 | 2003 | 911 | 0.050 | Why? | 
| Biomedical Research | 1 | 2007 | 556 | 0.050 | Why? | 
| Biological Transport, Active | 2 | 2002 | 89 | 0.040 | Why? | 
| Catheterization | 1 | 2002 | 238 | 0.040 | Why? | 
| Drug Resistance, Multiple | 1 | 2000 | 52 | 0.040 | Why? | 
| Predictive Value of Tests | 1 | 2006 | 2297 | 0.040 | Why? | 
| Sympatholytics | 1 | 1999 | 3 | 0.040 | Why? | 
| Anti-Infective Agents | 1 | 2002 | 277 | 0.040 | Why? | 
| Diuretics, Osmotic | 1 | 1999 | 4 | 0.040 | Why? | 
| Drug Carriers | 2 | 1992 | 118 | 0.040 | Why? | 
| Nifedipine | 1 | 1999 | 21 | 0.040 | Why? | 
| GABA Modulators | 1 | 1999 | 11 | 0.040 | Why? | 
| Tetradecanoylphorbol Acetate | 1 | 1999 | 69 | 0.040 | Why? | 
| Prostatic Neoplasms | 1 | 2009 | 1623 | 0.040 | Why? | 
| Middle Aged | 2 | 2017 | 29293 | 0.040 | Why? | 
| Tritium | 1 | 1999 | 170 | 0.040 | Why? | 
| Piperidines | 1 | 2021 | 238 | 0.040 | Why? | 
| Calcium Channel Blockers | 1 | 1999 | 117 | 0.040 | Why? | 
| Breast Neoplasms | 1 | 2012 | 2767 | 0.040 | Why? | 
| Microscopy, Electron | 1 | 1999 | 366 | 0.040 | Why? | 
| Adult | 2 | 2017 | 31872 | 0.040 | Why? | 
| Aged | 1 | 2017 | 21674 | 0.040 | Why? | 
| Base Sequence | 1 | 2003 | 3172 | 0.040 | Why? | 
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 259 | 0.040 | Why? | 
| Warfarin | 1 | 1999 | 125 | 0.040 | Why? | 
| Indoles | 1 | 1999 | 202 | 0.040 | Why? | 
| Purines | 1 | 1998 | 119 | 0.040 | Why? | 
| Pyridines | 1 | 1999 | 248 | 0.040 | Why? | 
| Ileum | 1 | 1998 | 136 | 0.040 | Why? | 
| Antineoplastic Agents, Hormonal | 1 | 1999 | 271 | 0.040 | Why? | 
| Mutation | 1 | 2012 | 6294 | 0.030 | Why? | 
| Duodenum | 1 | 1998 | 110 | 0.030 | Why? | 
| Infusions, Intravenous | 1 | 1999 | 571 | 0.030 | Why? | 
| Antibodies, Monoclonal | 1 | 2003 | 1068 | 0.030 | Why? | 
| Cytochrome P-450 CYP2A6 | 1 | 1996 | 14 | 0.030 | Why? | 
| Xenobiotics | 1 | 1996 | 29 | 0.030 | Why? | 
| Liposomes | 1 | 1997 | 207 | 0.030 | Why? | 
| Diffusion | 1 | 1995 | 58 | 0.030 | Why? | 
| Aging | 1 | 2003 | 1301 | 0.030 | Why? | 
| Neoplasms | 1 | 2010 | 3028 | 0.030 | Why? | 
| Basement Membrane | 1 | 1995 | 48 | 0.030 | Why? | 
| Ouabain | 1 | 1994 | 29 | 0.030 | Why? | 
| Amiloride | 1 | 1994 | 28 | 0.030 | Why? | 
| Hypoglycemic Agents | 1 | 1999 | 489 | 0.030 | Why? | 
| Hepatitis B virus | 1 | 2015 | 142 | 0.030 | Why? | 
| Anticoagulants | 1 | 1999 | 603 | 0.030 | Why? | 
| Adenocarcinoma | 2 | 2009 | 1070 | 0.030 | Why? | 
| Age Factors | 1 | 2021 | 2989 | 0.030 | Why? | 
| Intestinal Neoplasms | 1 | 1994 | 41 | 0.030 | Why? | 
| Diffusion Chambers, Culture | 1 | 1994 | 7 | 0.030 | Why? | 
| Subcellular Fractions | 1 | 1994 | 99 | 0.030 | Why? | 
| Insulin | 1 | 1999 | 1258 | 0.030 | Why? | 
| Gluconates | 1 | 2012 | 5 | 0.030 | Why? | 
| Recycling | 1 | 2012 | 5 | 0.030 | Why? | 
| Glucaric Acid | 1 | 2012 | 10 | 0.030 | Why? | 
| Uranyl Nitrate | 1 | 2012 | 3 | 0.020 | Why? | 
| Cell Proliferation | 2 | 2011 | 2554 | 0.020 | Why? | 
| Sodium Azide | 1 | 1992 | 4 | 0.020 | Why? | 
| Receptors, Interleukin-1 | 1 | 2012 | 29 | 0.020 | Why? | 
| Azides | 1 | 1992 | 9 | 0.020 | Why? | 
| Ions | 1 | 1992 | 24 | 0.020 | Why? | 
| Drug Dosage Calculations | 1 | 2012 | 21 | 0.020 | Why? | 
| Deoxyglucose | 1 | 1992 | 41 | 0.020 | Why? | 
| Inhibitory Concentration 50 | 1 | 2012 | 90 | 0.020 | Why? | 
| Injections, Subcutaneous | 1 | 2012 | 132 | 0.020 | Why? | 
| DNA Topoisomerase IV | 1 | 2012 | 13 | 0.020 | Why? | 
| Benzoxepins | 1 | 2011 | 1 | 0.020 | Why? | 
| 4-Nitroquinoline-1-oxide | 1 | 2011 | 8 | 0.020 | Why? | 
| DNA Gyrase | 1 | 2012 | 27 | 0.020 | Why? | 
| Limonins | 1 | 2011 | 3 | 0.020 | Why? | 
| Ofloxacin | 1 | 2012 | 32 | 0.020 | Why? | 
| Glucose | 2 | 2000 | 925 | 0.020 | Why? | 
| Levofloxacin | 1 | 2012 | 47 | 0.020 | Why? | 
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 60 | 0.020 | Why? | 
| Quinolones | 1 | 2012 | 57 | 0.020 | Why? | 
| Chemoprevention | 1 | 2011 | 58 | 0.020 | Why? | 
| Tyrosine | 1 | 2011 | 159 | 0.020 | Why? | 
| Creatinine | 1 | 2012 | 429 | 0.020 | Why? | 
| ErbB Receptors | 1 | 2011 | 303 | 0.020 | Why? | 
| Membrane Glycoproteins | 1 | 2012 | 432 | 0.020 | Why? | 
| Escherichia coli Infections | 1 | 2012 | 195 | 0.020 | Why? | 
| Cell Survival | 1 | 2012 | 889 | 0.020 | Why? | 
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 542 | 0.020 | Why? | 
| NF-KappaB Inhibitor alpha | 1 | 2009 | 35 | 0.020 | Why? | 
| I-kappa B Proteins | 1 | 2009 | 42 | 0.020 | Why? | 
| Kaplan-Meier Estimate | 1 | 2012 | 1142 | 0.020 | Why? | 
| Excipients | 1 | 1988 | 12 | 0.020 | Why? | 
| RNA, Messenger | 1 | 2015 | 2898 | 0.020 | Why? | 
| Anti-Inflammatory Agents | 1 | 2011 | 315 | 0.020 | Why? | 
| Transcription Factor RelA | 1 | 2009 | 57 | 0.020 | Why? | 
| Magnetic Resonance Spectroscopy | 1 | 2010 | 307 | 0.020 | Why? | 
| Gene Deletion | 1 | 2012 | 809 | 0.020 | Why? | 
| Basidiomycota | 1 | 2008 | 13 | 0.020 | Why? | 
| Cell Transformation, Neoplastic | 1 | 2011 | 644 | 0.020 | Why? | 
| Polymerase Chain Reaction | 1 | 2012 | 1624 | 0.020 | Why? | 
| Mathematics | 1 | 1988 | 96 | 0.020 | Why? | 
| beta-Lactams | 1 | 1988 | 55 | 0.020 | Why? | 
| Phosphorylation | 1 | 2011 | 1707 | 0.020 | Why? | 
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 2121 | 0.020 | Why? | 
| STAT3 Transcription Factor | 1 | 2009 | 230 | 0.020 | Why? | 
| Protein Binding | 1 | 1990 | 1844 | 0.020 | Why? | 
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 508 | 0.020 | Why? | 
| Pharmacokinetics | 1 | 2002 | 16 | 0.010 | Why? | 
| Mice, Inbred C57BL | 1 | 2012 | 4841 | 0.010 | Why? | 
| Cimetidine | 1 | 2000 | 15 | 0.010 | Why? | 
| Erythromycin | 1 | 2000 | 21 | 0.010 | Why? | 
| Atenolol | 1 | 2000 | 43 | 0.010 | Why? | 
| Insulin Lispro | 1 | 1999 | 2 | 0.010 | Why? | 
| Cresols | 1 | 1999 | 6 | 0.010 | Why? | 
| Adsorption | 1 | 1999 | 37 | 0.010 | Why? | 
| Mammals | 1 | 2000 | 280 | 0.010 | Why? | 
| Signal Transduction | 1 | 2009 | 4908 | 0.010 | Why? |